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To the Editor: When administered orally, isoniazid (INH),
which continues to form the basis of most first-line standard
antituberculosis regimens, reaches peak plasma concentrations
of 3 - 5 µg/ml within 1 - 2 hours after ingestion of usual doses.1
Various tablet and slow-release matrix forms are available and
these processed preparations are most often used clinically.
However, various studies undertaken in our Department have
shown  crystalline INH to produce better blood levels within
the first 2 hours after ingestion than the commonly used
tabletted form.2,3
We previously investigated the suitability of using
frozen/thawed human intestinal and vaginal mucosa for
performing in vitro bioavailability/bioequivalence (BA/BE)
studies for drug registration purposes.4 From these studies it
was clear that the above in vitro model showed promise,
particularly for studying therapeutic agents with molecular
weights < 500 Da.
This study aimed to further evaluate and validate the above
in vitro methodology for BA/BE purposes.
Materials and methods
Intestinal mucosa. Clinically healthy small intestine specimens
were obtained from 6 patients (2 males and 4 females), mean
age 61 ± 10 standard deviations (SD) (range 47 - 72) years,
following various surgical procedures at Tygerberg Hospital.
Specimens were transferred to our laboratory in transport
fluid within 1 hour, snap-frozen in liquid nitrogen and stored at 
– 85°C.4 After thawing, these specimens were used for
experiments as earlier studies failed to show significant flux
differences between fresh and frozen intestinal tissue.4
Only clinically healthy specimens were obtained and the
study was approved by the local Ethics Committee.
Drugs. Crystalline isonicotinic acid hydrazide (isoniazid
(INH)) (Fluka Chemie, Buchs, Switzerland) was made up to
100 mg/ml in PBS buffer (phosphate-buffered saline, pH 7.4).
Twenty tablets (100 mg INH each) (Be-Tabs Pharmaceuticals,
Roodepoort, South Africa) were weighed and pulverised in a
mortar. An aliquot (274.4 mg) of the powder, representing an
INH concentration of 100 mg, was suspended in 20 ml of PBS
buffer. Centrifugation separated insoluble tablet components
from the clear solution. Stability of the INH in PBS buffer was
monitored, no degradation (recovery = 99.8 ± 0.4%, N = 6)
being detected over the entire linear ( r = 0.99998, N = 6)
calibration range (1 - 20 µg/ml) over a period of 3 days.
Permeability experiments. Sections of thawed specimens
were mounted in flow-through diffusion cells and permeation
experiments performed as previously described.4 Before
experiments, specimens were equilibrated for 10 minutes with
PBS at 20° C in the apparatus. Thereafter, PBS was removed
from the donor compartment and replaced with either 1.5 ml of
5 µg/µl crystalline INH, or 5 µg/µl INH in PBS obtained from
tablets. PBS was pumped through the receiving chambers 
(1.5 ml/h) and collected at 2-hour intervals for 24 hours.
HPLC analysis of permeants. Permeant-containing samples
were derivatised with 1% (v/v) cinnamaldehyde in methanol
and analysed by means of high-performance liquid
chromatography (HPLC) using a Hewlett Packard 1090 L
instrument equipped with a Partecil 5 C8 250 mm column
(inner diameter = 4.6 mm) as previously described.5
Calculation of flux values. Flux (J) values across membranes
were calculated by means of the relationship J = Q/Ax t 
(µg/cm2/min), where Q = quantity of INH crossing membrane
(µg), A = membrane area exposed (cm 2) and t = time of
exposure (minutes).
Steady-state kinetics. When no statistically significant
differences (p < 0.05) (analysis of variance (ANOVA) and
Duncan’s multiple range test) between flux values were
obtained over at least two consecutive time intervals, a steady
state was assumed to have been reached for a particular
mucosal specimen and permeant.
Statistical analysis. An unpaired t-test with Welch’s
correction was used to investigate possible differences between
flux means at 2-hour intervals. A significance level of 5% was
used for all tests and comparisons.
Results
Overall mean flux values for crystalline and tabletted INH
across frozen/thawed intestinal mucosa versus time are shown
in Fig. 1. Steady-state flux conditions were reached after
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Fig. 1. Overall mean flux values for crystalline and tabletted INH
across frozen/thawed human intestinal tissue.
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approximately 8 hours. Flux rates of crystalline INH across
intestinal mucosa tended to be higher than those for tabletted
INH during the entire experiment, but were only significantly
different (p < 0.05) after 10 hours.
Discussion
We recently demonstrated that a continuous flow-through
mucosal perfusion system with intestinal mucosa showed
promise as an in vitro method for determining the permeability
of agents from the gastrointestinal tract for drug registration
purposes.4 However, simultaneously, we observed that
intestinal mucosa used in the above system was not very
permeable to molecules with weights (Mw) > 500 Da. We
therefore suggested that other mucosae, e.g. vaginal mucosa,
might have to be considered as substitutes if large Mw agents
are to be compared for BA/BE. Akin to other hydrophilic
compounds, INH (Mw = 137.14 Da) probably permeates the
intestinal mucosa via intercellular routes, the mucosal
membrane in conjunction with the epithelial tight junctions
providing the rate-limiting barrier.6
Although there was a tendency for flux rates of crystalline
INH to be higher than those of the tabletted form, these
differences were only significantly different after 10 hours (Fig.
1). A possible explanation is that the presence of the soluble
exipients in the tablets may alter the permeability properties of
INH across this barrier. However, it is clear that the intestinal
mucosal barrier appears to discriminate between the diffusion
rates of what is the same molecule with and without exipients.
In conclusion, we have shown that intestinal mucosa has
barrier properties which may be useful to assess BA/BE
properties of therapeutically active compounds in vitro. Further
studies using the above system are therefore indicated. 
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To the Editor: Asymptomatic patients may be referred for a
haematology opinion when the routine blood count reveals
elevation in haemoglobin level, haematocrit or red cell count.1
There is an all too cavalier approach to this abnormality, which
is not only an independent risk factor for arterial or venous
thromboembolic disease2 but may signal unsuspected
underlying cardiac  or pulmonary pathology.3 Infrequently
these findings may draw attention to an otherwise silent
myeloproliferative syndrome in the form of primary
proliferative polycythaemia or polycythaemia rubra vera of
old.4 Occasionally, and of major clinical importance, is
inappropriate erythropoietin production by tumours, including
kidney tumours.5
A systematic approach to this problem  is essential.1 The first
step is to distinguish spurious from absolute erythrocytosis by
simultaneous determination of red cell mass and plasma
volume6 since the latter may be independently reduced in a
number of situations, including cigarette smoking.7 In the
majority of cases the most common cause is found in the lungs
with desaturation that enhances normal erythropoietin
production via a renal sensing mechanism. Less frequently
encountered is right-to-left shunting at the level of the heart or
the great vessels. Conversely, increases in neutrophil and
platelet count signal autonomous haematopoiesis in chronic
myeloproliferative syndromes. Less frequent, but of major
importance, is the need to recognise individuals with ectopic
production of erythropoietin; of these the classic example
remains cerebellar haemangioblastoma.1 More common causes
are found in renal cell carcinoma,5 uterine fibroids,8 and
haemangiomas of the liver9 and lung.10
A case is reported here to illustrate the occurrence of
symptomatic expansion of red cell mass as a reminder to
search carefully for otherwise silent tumours in this clinical
context.
A 54-year-old woman was referred by her primary care
physician with a haemoglobin of 183 g/l, a packed cell volume
of 55%, and normal platelet and white cell count. Her history
dated back 6 weeks. While at a health farm she had had routine
blood tests done primarily to define her endocrine status as a
basis for postmenopausal hormone replacement therapy.
Seventy-five per cent thyroidectomy had been carried out 3
years previously for a benign lesion. She was on 100 µg of
Clinically silent renal tumour producing erythropoietin
